Família ABC Arquivos Brasileiros de Cardiologia International Journal of Cardiovascular Sciences ABC Heart Failure & Cardiomyopathy ABC Imagem Cardiovascular
Português English
Família ABC
Português English
  • Sobre
    • Sobre a Família ABC
    • Regimento Interno
    • Conselho Editorial
    • Sociedade Brasileira de Cardiologia (SBC)
  • Edições
  • Diretrizes da SBC
  • Conteúdos
    • Vídeos
    • Podcasts
    • Notícias
  • Sobre
    • Sobre a Família ABC
    • Regimento Interno
    • Conselho Editorial
    • Sociedade Brasileira de Cardiologia (SBC)
  • Edições
  • Diretrizes da SBC
  • Conteúdos
    • Vídeos
    • Podcasts
    • Notícias

Família ABC

  • Família ABC
  • Arquivos Brasileiros de Cardiologia
  • International Journal of Cardiovascular Sciences
  • ABC Heart Failure & Cardiomyopathy
  • ABC Imagem Cardiovascular
Buscar em

Nenhum conteúdo encontrado.

Revistas
Ordenação
Tipos de artigo
Outros

  1. Início
  2. Palavra-chave: Dyspnea
IJCS
Viewpoint

Challenges in Pharmacological Management of Cardiovascular Diseases in Covid-19: do Benefits Outweigh Risks?

Samuel de Sousa Pedro et al. Fernanda Carla Ferreira de Brito Christianne Bretas Vieira Scaramello

Introduction

Cardiovascular diseases (CVD) are the main cause not only of global mortality but also of reduced quality of life. They cover ischemic heart disease, stroke, heart failure, peripheral artery disease, and various other heart and vascular conditions. In 2017, CVDs caused about 17.8 million deaths worldwide, corresponding to 330 million years of life lost and another 35.6 million years of life with disabilities. Almost 80% of deaths occur in low- and middle-income countries, such as Brazil, where the occurrence of CVDs and their risk factors are on the rise as a result of an ongoing epidemiological transition. In low-income countries CVDs greatly affect working-age populations, and the total economic loss resulting from this group of diseases is high, representing 2% of Gross Domestic Product. In addition, the disability caused by CVDs has economic consequences at multiple levels: individual, family, economic agents, public institutions, government, and society as a whole.

Recent studies also show that chronic conditions, such as CVD, increase the risk of aggravation and death associated with the new coronavirus 2019 disease (COVID-19), whose outbreak was characterized as a pandemic by the World Health Organization (WHO) in March 2020. The new coronavirus is a betacoronavirus called SARS-CoV-2 (Severe Acute Respiratory Syndrome coronavirus 2), phylogenetically identical to other coronaviruses capable of determining acute respiratory distress syndrome (ARDS), which is responsible for numerous deaths. The most common symptoms of COVID-19 include fever, cough, dyspnea, myalgia, fatigue, diarrhea, sore throat, chest pain, confusion, and lethargy. Acute and chronic cardiovascular complications have also been observed in the course of COVID-19, being attributed to several mechanisms, such as relative ischemia, systemic inflammation mediated by pathogens, with increased levels of several biomarkers. In this context, studies point to the relevance not only of chronic conditions, such as hypertension, but also of the age and immunological status of the host, characterizing a complex, multifactorial, and bidirectional model that can comprehend the drugs used to treat these pathologies.

[…]

  • Anticoagulants
  • Cardiovascular Diseases, mortality
  • Coronavirus/complications
  • Covid-19/complications
  • Dyspnea
  • Fever
  • Pandemics
  • SARS Severe Acute Respiratory Syndrome
Ler artigo completo
Creative Commons Attribution (CC BY) Creative Commons license
31/07/2020 DOI: 10.36660/ijcs.20200081
IJCS
Viewpoint

Covid-19 and Safety in the Cath Lab: Where We Are and Where We Are Headed

Giordana Zeferino Mariano et al. Viviana Guzzo Lemke Maria Sanali Moura Paiva Gláucia Maria Moraes de Oliveira

Safety measures in the procedure preparation stage

A study conducted in China with 72,314 patients with COVID-19 (44,672 laboratory-confirmed cases, 16,186 suspected cases, and 10,567 clinically diagnosed cases) has reported fever, cough, dyspnea, myalgia, fatigue and diarrhea as the most common symptoms. Other signs and symptoms have been reported, such as sore throat, chest pain, mental confusion, and lethargy. The authors have highlighted that COVID-19 had a benign course in 80% of the cases, and that many patients, although asymptomatic, could carry the virus. It is worth noting the importance of the differential diagnosis of dyspnea and fatigue, especially when associated with the other symptoms.

During a respiratory pandemic, patients and their families should be informed about the risks of contamination, despite all additional measures taken to minimize them. Because the number of elective procedures will be drastically reduced during that period, the length of hospital stay is predicted to be the minimum necessary for each protocol consensually elaborated. Moreover, defining a procedure as elective requires clinical judgement, because postponing it might have effects that will increase the likelihood of decompensation and adverse events during the pandemic, such as in high-risk patients with unstable angina. Therefore, the decision about performing a procedure should be individualized and based on the patient’s risk and benefit analysis.

[…]

  • chest pain
  • Coronavírus
  • Cough
  • COVID-19
  • Diarrhea
  • Dyspnea
  • Fatigue
  • Fever
  • Mental Confusion
  • Myalgia, Cardiovascular Diseases/complications
  • Pandemics
  • Pathological Conditions, Signs and Symptoms
  • Safety
Ler artigo completo
Creative Commons Attribution (CC BY) Creative Commons license
29/05/2020 DOI: 10.36660/ijcs.20200080 Visualizações 1
IJCS
Editorial

COVID-19: A Matter Close to the Heart

Gláucia Maria Moraes de Oliveira et al. Fausto J. Pinto

The world is facing a new challenge, the novel coronavirus disease 2019 (COVID-19), caused by a betacoronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), phylogenetically identical to the SARS-CoV (severe acute respiratory syndrome coronavirus) and the MERS-CoV (Middle East respiratory syndrome coronavirus) responsible for innumerable deaths in China in 2003 and in the Middle East in 2012, respectively.

On March 11, 2020, the COVID-19 outbreak was characterized as a pandemic by the World Health Organization (WHO). Twenty-three days after that announcement, the cases reported reached 1,056,777 in 182 countries, with 55,781 deaths, most of which occurring in Italy, Spain, France, China and Iran. So far, Brazil has registered 8,195 cases and 335 deaths, while Portugal, 9,886 cases and 246 deaths, figures that have increased steeply since the beginning of the pandemic.

[…]

  • Cardiovascular Diseases/complications
  • Coronavirus-19 (COVID-19
  • Dyspnea
  • Fever
  • Mortality
  • Pandemics
  • Risk Factors
  • Severe Acute Respiratory Syndrome
Ler artigo completo
Creative Commons Attribution (CC BY) Creative Commons license
17/04/2020 DOI: 10.36660/ijcs.20200057

Como citar este artigo

EndNote RIS

Formato de Documento Eletrônico (Vancouver)

Pedro SS, Brito FCF, Scaramello CBV. Challenges in Pharmacological Management of Cardiovascular Diseases in Covid-19: do Benefits Outweigh Risks?. International Journal of Cardiovascular Sciences 2020;33(4):404-11.

Formato de Documento Eletrônico (ABNT)

Pedro, Samuel de Sousa; Brito, Fernanda Carla Ferreira de; Scaramello, Christianne Bretas Vieira. Challenges in Pharmacological Management of Cardiovascular Diseases in Covid-19: do Benefits Outweigh Risks?. International Journal of Cardiovascular Sciences, v. 33, n. 4, p. 404-411, jul. 2020.

Formato de Documento Eletrônico (APA)

Pedro, S. S., Brito, F. C. F. , & Scaramello, C. B. V. (2020). Challenges in Pharmacological Management of Cardiovascular Diseases in Covid-19: do Benefits Outweigh Risks?. International Journal of Cardiovascular Sciences, 33(4), 404-411.

Formato de Documento Eletrônico (ISO)

Pedro, Samuel de Sousa and Brito, Fernanda Carla Ferreira de and Scaramello, Christianne Bretas Vieira. Challenges in Pharmacological Management of Cardiovascular Diseases in Covid-19: do Benefits Outweigh Risks?. International Journal of Cardiovascular Sciences [online]. 2020, vol. 33, n. 4, [citado 2026-10-14], pp. 404-411. Disponível em: <https://journals.cardiol.br/article/challenges-in-pharmacological-management-of-cardiovascular-diseases-in-covid-19-do-benefits-outweigh-risks-2/>. ISSN 2359-4802

EndNote RIS

Formato de Documento Eletrônico (Vancouver)

Mariano GZ, Lemke VG, Paiva MSM, Oliveira GMM. Covid-19 and Safety in the Cath Lab: Where We Are and Where We Are Headed. International Journal of Cardiovascular Sciences 2020;33(3):288-94.

Formato de Documento Eletrônico (ABNT)

Mariano, Giordana Zeferino; Lemke, Viviana Guzzo; Paiva, Maria Sanali Moura; Oliveira, Gláucia Maria Moraes de. Covid-19 and Safety in the Cath Lab: Where We Are and Where We Are Headed. International Journal of Cardiovascular Sciences, v. 33, n. 3, p. 288-294, maio. 2020.

Formato de Documento Eletrônico (APA)

Mariano, G. Z., Lemke, V. G., Paiva, M. S. M., & Oliveira, G. M. M. (2020). Covid-19 and Safety in the Cath Lab: Where We Are and Where We Are Headed. International Journal of Cardiovascular Sciences, 33(3), 288-294.

Formato de Documento Eletrônico (ISO)

Mariano, Giordana Zeferino and Lemke, Viviana Guzzo and Paiva, Maria Sanali Moura and Oliveira, Gláucia Maria Moraes de. Covid-19 and Safety in the Cath Lab: Where We Are and Where We Are Headed. International Journal of Cardiovascular Sciences [online]. 2020, vol. 33, n. 3, [citado 2026-10-14], pp. 288-294. Disponível em: <https://journals.cardiol.br/article/covid-19-and-safety-in-the-cath-lab-where-we-are-and-where-we-are-headed-2/>. ISSN 2359-4802

EndNote RIS

Formato de Documento Eletrônico (Vancouver)

Oliveira GMM, Pinto FJ. COVID-19: A Matter Close to the Heart. International Journal of Cardiovascular Sciences 2020;33(3):199-202.

Formato de Documento Eletrônico (ABNT)

Oliveira, Gláucia Maria Moraes de; Pinto, Fausto J.. COVID-19: A Matter Close to the Heart. International Journal of Cardiovascular Sciences, v. 33, n. 3, p. 199-202, abr. 2020.

Formato de Documento Eletrônico (APA)

Oliveira, G. M. M. , & Pinto, F. J. (2020). COVID-19: A Matter Close to the Heart. International Journal of Cardiovascular Sciences, 33(3), 199-202.

Formato de Documento Eletrônico (ISO)

Oliveira, Gláucia Maria Moraes de and Pinto, Fausto J.. COVID-19: A Matter Close to the Heart. International Journal of Cardiovascular Sciences [online]. 2020, vol. 33, n. 3, [citado 2026-10-14], pp. 199-202. Disponível em: <https://journals.cardiol.br/article/covid-19-a-matter-close-to-the-heart-2/>. ISSN 2359-4802

  • Sobre a Família ABC
  • Regimento Interno
  • Conselho Editorial
  • Sociedade Brasileira de Cardiologia (SBC)

Edições

Diretrizes da SBC

  • Vídeos
  • Podcasts
  • Notícias